Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.

Read More »

Roche’s lung cancer combo treatment wins FDA approval

Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.

Read More »

AbbVie’s Rova-T Sees Another Failure

AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

Read More »

Roche’s Tecentriq wins speedy U.S. FDA review for small cell lung cancer

Swiss group Roche Holding AG said the company’s Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.

Read More »

BMS Teams with Two UK Research Groups to Create Lung Cancer Rule Book

Bristol-Myers Squibb is teaming up with Cancer Research UK and the Francis Crick Institute to create guidelines for immuno-oncology therapy development focused on lung cancer treatments.

Read More »

FDA approves Catalyst Pharma’s rare disease drug

The U.S. Food and Drug Administration approved Catalyst Pharmaceuticals Inc.’s drug Firdapse to treat a rare autoimmune disease.

Read More »

Key AstraZeneca lung cancer treatment misses study goal

AstraZeneca said the immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on the company’s shares.

Read More »

FDA approves Pfizer’s Lorbrena treatment for certain lung cancer patients

The U.S. Food and Drug Administration approved Pfizer Inc.’s lung-cancer treatment Lorbrena for patients with a specific gene mutation who had been previously treated for an aggressive form of the disease.

Read More »

FDA Approves Another Indication for Merck’s Keytruda

Merck’s blockbuster anti-PD-1 therapy Keytruda won FDA approval in combination with chemotherapy as a first-line treatment for patients with metastatic squamous non-small cell lung cancer.

Read More »

FDA Action Alert: Merck’s Keytruda in Lung Cancer, Trevena and AcelRx Drugs for Pain

Several PDUFA action dates for drug applications are up for review by the Food and Drug Administration.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom